reference populations for each compound or compound combination tested. The information is then compiled in an easily actionable report that is delivered to the treating physician within 21 days after tumor tissue sampling. The report The treating physician receives a simpleto-read and practical report showing the sensitivity of that patient’s tumoroids, classified as low, medium and high sensitivity profile for each of the drugs in the requested panel. This information can then be considered in the decision-making about which course of treatment to take. Examples of the growth inhibition curves and results-table provided in each IndiTreat® report 5FU FOLFOX FOLFIRI FOLFOXIRI Drug tested Low sensitivity Medium sensitivity High sensitivity 5-fluorouracil (5FU) • FOLFOX • FOLFIRI • FOLFOXIRI • Low Medium High Current patient Sensitivity 1 Dillekas H et al.: Cancer Med. 2019; 8: 5574–5576. https://doi.org/10.1002/cam4.2474, ² Jeppesen M et al.: 2017. PLoS ONE 12(9): e0183074. https://doi. org/10.1371/ journal.pone.018307 Test Requisition Sample Reception Tumoroid Generation Tumoroid Culture Tumoroid Biobank Drug Screening Image Analysis Patient Report Patient Treatment Result Validation IndiNet AI IndiBase LIMS Sample Flow Information Flow The IndiTreat® process flow If you would like to know more about our technology. please don’t hesitate to contact us via support@2curex.com
RkJQdWJsaXNoZXIy ODY1MjQ=